# ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

> **NCT06328738** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Enliven Therapeutics** · enrollment: 275 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER2 Positive Solid Tumors
- HER2 Amplification
- Colorectal Cancer

## Interventions

- **DRUG:** ELVN-002
- **DRUG:** Trastuzumab
- **DRUG:** 5-Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Eribulin
- **DRUG:** paclitaxel
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT06328738
- **Lead sponsor:** Enliven Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2027-01
- **Final completion:** 2028-07
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328738, "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06328738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*